Health awareness

Empowering others to speak up about HPV-related cancers

The impact of Gina’s diagnosis inspired her to help others prioritize their health

January 5, 2024

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

After 20 years of normal cervical screenings,* Gina Esposito was confident her next routine screening wouldn’t be any different. So, when she was diagnosed with human papillomavirus (HPV)-related cervical precancer at 47 years old, she was surprised.

“The sinking feeling I had when I received my diagnosis was intense because I wasn’t expecting it,” she said.

*A cervical screening, often referred to as a pap test or pap smear, looks for precancers or cell changes that might become cervical cancer if not treated appropriately.

The impact of HPV-related cancers and diseases

More than 80% of cervical cancers are associated with HPV. For most people, HPV clears on its own. But for those who don’t clear the virus, it could cause certain cancers and diseases.

After her diagnosis, Esposito underwent a procedure to remove the abnormal cells from her cervix. When a follow-up test showed that there were still some abnormal cells present, she consulted with a doctor and decided to get a hysterectomy.

At first, she felt embarrassed by her diagnosis. As she started to share her story, she noticed that others felt ashamed to speak about HPV-related cancers and diseases. She knew something had to change.

“I have a newfound responsibility to take the stigma away, to say ‘the shame has to go away,’ whether you’re a woman or a man,” Esposito said.

Throughout her experience, she says her daughter has been a source of strength.

“You don’t want your child to be without you or to experience the loss of a parent. You want to be around for all of their milestones and they want you around,” Esposito said. “So, she keeps me motivated because there’s an expectation that mom’s going to be around.”

Gina Esposito HPV Story Image 2

“I try to be a positive disruptor in this space and normalize it so that people go for early screenings and routine screenings and that they get treatment if they need it.”

— Gina Esposito

The importance of routine care

In some ways, Esposito considers herself lucky. Her commitment to prioritizing routine care helped her catch her disease early.

“I’m so glad I took the time to go to my screening – it helped catch my disease early,” she said.

Esposito is working to ensure her daughter also prioritizes getting routine care and understands the value of prioritizing her health, especially as she approaches adulthood.

“She knows you need to own your own health because no one else is going to do it for you,” she said. Esposito encourages colleagues across our company to prioritize their health, too.

Esposito plans to continue helping men and women feel comfortable discussing HPV-related disease and get the preventative care they need.

“When I talk with others, I focus on what happened to me so they can use it as an example,” Esposito said. “I get people emailing me, texting me, going, ‘I’m going to make my appointment today.’ And if we can have one person that we get early, then my job is done.”

Innovation

Harnessing innovative technology in drug discovery

Merck scientists explain how new technologies can accelerate the drug discovery process as we use the power of leading-edge science to save and improve lives

November 16, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Our scientists are leveraging state-of-the-art capabilities to discover novel molecules that may lead to the medicines of tomorrow. 

Merck Research Laboratories (MRL) scientists evaluate hundreds to thousands to up to billions of compounds to find a starting point for a new drug candidate. It all starts with identifying a target — usually a protein — that’s intrinsically associated with a particular disease and can be pharmacologically modulated. That’s where innovative tools like structure-based design, high-throughput screening and high-throughput experimentation, coupled with robotics, artificial intelligence and machine learning can make a huge difference in progressing the work. And once a lead molecule is identified, cryogenic electron microscopy (cryo-EM) as an emerging structural method can be used to understand and improve how a molecule interacts with the protein target.

Utilizing the latest technologies and diligent work by teams of highly skilled and experienced scientists can potentially accelerate the discovery of new medicines for patients in need.

“We have an incredibly creative, smart and hardworking workforce. It’s an absolute pleasure to be part of that and to have access to the resources necessary for making scientific breakthroughs.”

— Adam Weinglass

Executive director in quantitative biosciences
Health awareness

Staying positive with pulmonary arterial hypertension

From struggling to breathe to advocating for others, one woman with PAH shares her story

October 24, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

A decade ago, Nola Martin was having trouble breathing, and she was gaining weight. She assumed it was simple: She started to focus on improving her diet and getting more exercise, but she wasn’t seeing results.

“Little did I know the situation was a lot more serious than that,” she said.

Martin was diagnosed with pulmonary arterial hypertension (PAH) and scleroderma. PAH is a disease of high blood pressure in the lungs. Her PAH was associated with scleroderma, a connective tissue disease that can affect the skin, blood vessels and organs and can cause PAH.

“I had two illnesses, and I had no idea what they were from. How did I get them? I was hearing all these terms I’d never heard of before.”

  • Nola Martin

Finding the right care

Martin said that the confusion and complexity of having two chronic diseases made the beginning of her journey the most challenging. Through her experience with PAH, she said she learned that “you must find a facility that is familiar with your disease.” She recommends the Pulmonary Hypertension Association as a great place to start learning about PAH.

While she knows her PAH is progressive, she chooses to stay positive.

“What I learned about advocating for myself with PAH is that no one is going to fight as hard for me as I will,” said Martin. “I know my body. I know when something is different, but I also know that my doctors are not mind readers. If I don’t share with them what is going on, including the smallest details, they can’t give me the proper treatment I need.”

portrait of women in orange shirt

Staying hopeful through connection

It’s important to Martin to connect with other PAH patients and educate people about the disease.

Since her diagnosis, she’s educated numerous people about PAH and scleroderma. She believes in the importance of raising awareness and telling her story. It’s sometimes hard for her to explain to people that even if she doesn’t appear sick, she may still be dealing with difficult symptoms.

“PAH has affected so much of my daily life — simple things like vacuuming, doing the laundry, taking a shower and going to the grocery store,” Martin said. “I encourage others to be understanding and avoid making assumptions about a person with PAH based on their outward appearance.”

She urges people to be supportive and listen when someone shares their story.

Innovation

Merck’s legacy of antimicrobial innovation and action

Delivering on our commitment to fight infectious diseases for more than a century

October 12, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientist working with liquid

For more than 100 years, Merck has contributed to the discovery and development of novel medicines and vaccines to fight infectious diseases. With the growing burden of antimicrobial resistance (AMR), we’ve focused on stopping the increasing threat of AMR

1930s

Merck Research Laboratories played a central role in the development of sulfas, the first synthetic antimicrobial.

vials with background of industrial complex

1940s

In collaboration with Rutgers University, we developed streptomycin, the first antibiotic effective against tuberculosis. We also helped to develop one of the first methods for mass production of penicillin.

scientist taking out trey of vial

1950s & 1960s

We developed multiple novel methods to prevent infectious diseases, including pediatric vaccines.

scientist working with equipment

1970s & 1980s

We received U.S. Food and Drug Administration (FDA) approval for two vaccines, as well as three antibiotics that treat a variety of bacterial infections.

doctor holding patients right arm

1990s & 2000s

Merck received U.S. FDA approval for two antifungals, as well as licenses for two vaccines.​

2002

With resistance to antibiotics developing faster through people, animals and the environment, we launched one of the world’s largest and longest-running antimicrobial resistance surveillance studies. Called the Study for Monitoring Antimicrobial Resistance Trends (SMART), the program enables researchers to monitor and identify trends in the development of AMR.

2010s

We launched an Antimicrobial Stewardship (AMS) Investigator Initiated Studies program, supporting investigator-based, peer-reviewed research supporting the implementation of AMS principles across the globe, with over 20% of studies occurring in low-and middle-income countries.

large building

2016

We created the Merck Exploratory Science Center in Cambridge, Massachusetts, focusing on the earliest stages of research into the underlying biology of human disease.

2016-2017

We supported the first United Nations high-level meeting on AMR and subsequent political declaration in 2016, which set policy action on AMR in motion.

As a next step, we joined the newly founded AMR Industry Alliance – a network of over 100 pharmaceutical industry partners working to provide sustainable solutions to help curb antimicrobial resistance.

AMR action fund logo

2020

Merck, along with a group of more than 20 leading biopharmaceutical companies, launched the AMR Action Fund to bring 2-4 new antibiotics to patients by the end of the decade.

2020s

Our staff have championed government actions to create supportive markets for antimicrobial innovation, including the PASTEUR Act in the U.S., inclusion of transferable exclusivity extensions in the EU pharmaceutical strategy, and other incentives around the world.

By collaborating with policymakers, Merck aims to improve appropriate antibiotic use globally.

cow drinking milk from bottle

Going forward

In recognition of our leadership in both human and animal health, Merck represents industry in the One Health Global Leaders Group on Antimicrobial Resistance, which advocates for a One Health approach to help ensure antibiotics remain an important tool in improving and maintaining human and animal health.

Innovation

Podcast: Why neuroscience is the ‘final frontier’

Listen as specialists from Merck discuss what they’re most excited about in researching potential treatments for neurologic disorders

July 11, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Four people in a modern office setting, with two seated on blue chairs and two standing behind them

Our scientists are revolutionizing how we discover and develop treatments to address unmet medical needs in a number of areas, including neuroscience.

“It’s sort of like the final frontier,” said Joe Herring, scientific AVP, clinical research, in our new podcast. “You’re going off into space to try to figure out how to do very difficult things.”

For more, listen in as Herring sits down with Merck clinical research team senior principal scientists Yuki Mukai and Ari Merola as well as business development director Paige Lacatena to explore today’s breakthroughs and challenges in the field of neuroscience.

Listen to the podcast

Read the full transcript

Explore careers in R&D at Merck

Man and women scientists in a lab

Careers

Are you interested in a career in R&D?

Our people

Podcast: Meet the dealmakers 

Merck’s business development and licensing team explain how they identify new opportunities to strengthen our robust R&D pipeline  

June 1, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

PodcastGroupattable

It takes a special kind of talent to find and secure the right deals to keep us at the forefront of innovation. Leaders from our business development and licensing team sat down to discuss how their work is a key component to building and maintaining a strong pipeline.  

Here’s what you need to know:  

01.

Harnessing our legacy

Our reputation for using leading-edge science can make business development connections easier, explains Lizabeth Leveille, vice president, business development.


02.

The speed and determination to get it done

Elizabeth Naldi-Jacob, vice president, business development, knows that having a direct line of reporting to the top is what sets Merck apart as a potential partner. 


03.

Balancing the internal and the external  

We have a one pipeline mindset, and each asset receives the same focus and rigor whether it comes from inside our company or out, says Christopher Mortko, vice president, business development. 


04.

Working hand-in-hand with our scientists  

Grace Han McMahon, associate vice president, business development, explains why engaging our internal science leaders is crucial to making the right deals. 


05.

What we’re interested in (and why it’s everything) 

Our panelists discuss why we focus on five key areas — and when we’re willing to look beyond them.


Great partnerships begin with great conversation. Learn more about how discovery & development and licensing shape the future of Merck.  

For more, check out the full podcast: 

four people behind the mic on the right stating meet the dealmakers on the left

Read the transcript

Our people

Here for Good: Bridging the gap between bedside and bench

Members of Merck’s lung cancer clinical development team say working in the hospital inspired their drive to innovate for patients

May 24, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Dr. Ayman Samkari remembers how treating patients during his medical school rotations brought him face to face with the unmet needs of people with cancer. He learned to listen to what matters for patients beyond their diagnoses, and he sought new ways to make a greater impact as an oncologist.

Watch Samkari and Dr. Nazly Shariati discuss their passion for their work:

primary article image

“Even though I enjoyed every moment of practicing medicine and treating patients with cancer, I had the question at the back of my mind: How can I do things differently? How can I improve patient outcomes?” recalled Samkari, who now works for Merck as executive director in oncology clinical development. “That’s what drove me to pursue my career in clinical research, where I could help patients on a larger scale.”

And after 25 years as a surgeon, when a hand ailment ultimately sidelined her in the operating room, Dr. Nazly Shariati found that research was another avenue to help more patients.

portrait of women with grey hair

“Merck allowed me to not only fulfill my goals in life and my career but continue on my path to have an impact on patients’ lives.”

— Dr. Nazly Shariati

Senior principal scientist in oncology clinical development

From careers in clinical care to careers in research

Samkari’s background as an oncologist, and Shariati’s as a surgeon, have informed their work in our lung cancer clinical development program. All too familiar with the challenges of treating patients with advanced disease, Samkari and Shariati are shifting their research to investigating lung cancer at its earlier stages, before it has spread, when it’s more likely to be successfully treated.

When she was a cardiothoracic surgeon, Shariati often felt a sinking feeling whenever a patient’s lung cancer would return, which is common among people diagnosed with lung cancer that was removed surgically. But today she’s excited by scientific advances in resectable lung cancer focused on helping more patients.

Understanding the patient experience

Shariati said understanding the patient experience is what drives a researcher’s passion, innovation and desire to help others.

Ayman Samkari

“It is very important to have that experience in managing and seeing patients because it gives you a completely different perspective on how you conduct your work.”

— Dr. Ayman Samkari

Executive director in oncology clinical development

Each day, Samkari and Shariati continue to push the boundaries in research to help make a difference for people living with cancer.

Innovation

Individualized neoantigen therapies: exploring one medicine for one patient

Scientists are researching new ways to help train the immune system to fight cancer

April 13, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Over the past decade, immunotherapy has transformed our understanding of how the immune system can be used to help fight some types of cancer. However, for the last 50 years, scientists have been researching how we could potentially use vaccines to treat cancer — another investigational approach to harness the immune system to help recognize and destroy cancer cells — with little success.

Now we’re looking at a potential therapy that is building upon the learnings of immunotherapy trials from the past and incorporating that into an individualized cancer approach that’s specific to a patient’s own tumor. Researchers are currently exploring the potential of individualized neoantigen therapies to help fight cancer.

Cancer research is becoming more personalized

Cancer is a result of the body’s own cells undergoing mutations which create abnormal proteins in cancer cells, known as neoantigens, that are not usually seen in normal cells. These mutations are unique to each person’s tumor, so that’s one of the reasons why patients who have been diagnosed with the same type of cancer and who have received the same type of treatment may have different responses.

As the treatment of cancer continues to evolve and advance, researchers are focusing on more individualized approaches. This includes a new area of research into individualized neoantigen therapies that use information from a person’s tumor biopsy sample to help develop a therapy unique to their tumor’s mutations.

Merck's Dr. Jane Healy

“This area of research has really captured our imagination of what’s possible in the development of cancer therapeutics.”

  • Dr. Jane Healy
    Vice president and head of oncology early development at Merck Research Laboratories

In collaboration with Moderna, we’re studying this area of research in an effort to advance more individualized approaches to help improve outcomes for people living with cancer.

Learn more about individualized neoantigen therapies

infographic of what is an individual neoantigen therapy
Health awareness

Heart failure: A physician’s perspective

By Dr. Joerg Koglin, senior vice president and head of general medicine and global clinical development

April 5, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Joerg Koglin Hero

According to the American Heart Association, 127.9 million adults in the U.S. — nearly half of all U.S. adults — have some type of cardiovascular disease. And the implications can be very serious. In fact, cardiovascular disease is the leading cause of death in the U.S., claiming approximately 940,000 lives each year (based on 2022 estimates). There are many types of cardiovascular diseases, one of which is heart failure. Heart failure is when the heart cannot pump properly so that it doesn’t fully support the body’s need for oxygen and blood. And that is where my specialty and passion lie. As a cardiologist, I learned and study how cardiovascular diseases develop to try to find ways to help manage conditions that impact so many people around the world.

For years, I worked in one of the largest European academic centers focused on heart failure and cared for patients with this chronic, progressive condition. I saw how this disease affected my patients’ lives and what it meant to live with its symptoms: swollen feet, legs and ankles; shortness of breath; persistent coughing; and fatigue.

After many years as a physician treating individual patients in a heart failure clinic, I joined the Merck research team to try and impact patient care at a larger scale, but I still carry my patients’ stories with me. I remember the father trying to keep up with his kids, losing his breath just climbing the bleachers at a game. The husband who was waiting on the heart transplant list, but ran out of time. My patients’ struggles with heart failure and the impact it had on their families is what drives my desire to make a difference. They are a big part of why I’m at Merck today, working with a team of world-class scientists to try to advance heart failure research.

Our focus is on trying to help people with heart failure, which impacts more than six million Americans — a number that is expected to grow to over eight million by 2030. We’re working with a sense of urgency because the prognosis for people with heart failure is poor.

While heart failure is a challenging disease, I’m hopeful about the future of research. More than 60 years ago, my colleagues at Merck delivered their first advance in cardiovascular disease and, today, we’ll keep pushing heart failure research forward.

While science pushes forward, it’s important for all of us to take steps today to protect our hearts by living as healthy a lifestyle as possible. The advice I try to follow myself is all about creating healthy habits: eating healthy food, which means more fresh fruits and vegetables and fewer processed foods; maintaining a healthy weight; getting regular exercise and not smoking. With the busy and hectic lifestyles many of us lead, it can be hard to fit it all in every day, but every little bit counts. I’ve found that in life as in science, small steps, coupled with persistence and dedication, can help make a difference.

Our people

VIDEO: Here for Good – When passion and curiosity fuel innovation

Hear how one of our scientists balances her work and family life to accelerate our groundbreaking research

February 2, 2023

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Testing experiments in a lab can be a lot like raising kids. Sometimes your molecules do what you want them to do, and sometimes they don’t. But it’s a challenge Denarra Simmons, a senior scientist at Merck and a mother of two, is always up for.

“You’re constantly trying to find other medicines because all medicines don’t work the same way for all people,” Simmons said.

“You spend the long nights thinking about experiments, how to make things better, how to move things faster to help more people.”

— Denarra Simmons

female scientist in a lab

Simmons has been curious about how and why things work for most of her life. As a young child, she peppered her family with questions, trying to understand the “why” behind anything and everything. But it wasn’t until a man in a lab coat came to her grade school to talk about his career that she realized what her true passion was.

“He wrote an equation on the board and was talking about how people made medicines, and I thought that was fascinating,” Simmons said. “But the thing that really drew my attention was how excited he was when he was explaining what he did. I wanted to do something that I would love that much and over time, I realized that for me, it was science and helping people.”

For 12 years, Simmons has funneled that passion into her research at Merck. Simmons works in drug development to test the efficacy and safety of our biologic medicines used for investigational new drug (IND) enabling studies.

“Working in the lab is my favorite part of my job — and getting good data."

Woman, man and two children smiling

Some days in the lab may be more successful than others, and Simmons uses it all to show her children what it takes to be a scientist. “Good days are celebrated, and the tricky days, we keep working towards improving,” she said.

Simmons also feels strongly about teaching her children that there’s more to life than work.

“I’m always thinking about the experiments, but when I’m home with the children, I really try to give them the attention and time they need,” she said.

But once her daughter and son finish their homework and head to bed, Simmons finds herself thinking about her next set of experiments.

“When you find out a medicine you worked on has helped so many people, you feel really special and you know all the work has been worthwhile,” she said. “And that’s why you’re doing what you do: you’re making a difference in society.”